FDA Approves Herceptin Biosimilar Trazimera for HER2-Positive BC

Options
Moderators
Moderators Member Posts: 25,912

FDA Approves Herceptin Biosimilar Trazimera to Treat HER2-Positive Breast Cancer
March 18, 2019

On March 11, 2019, the FDA approved Trazimera (chemical name: trastuzumab-qyyp), a biosimilar for Herceptin, to treat people diagnosed with HER2-positive breast cancer. Read more...

Categories